StockNews.com Begins Coverage on FibroGen (NASDAQ:FGEN)

by · The Cerbat Gem

StockNews.com started coverage on shares of FibroGen (NASDAQ:FGEN – Free Report) in a report published on Tuesday. The firm issued a hold rating on the biopharmaceutical company’s stock.

FibroGen Stock Performance

Shares of FGEN stock opened at $0.32 on Tuesday. The stock’s 50-day moving average is $0.37 and its two-hundred day moving average is $0.77. FibroGen has a 1 year low of $0.29 and a 1 year high of $2.93. The firm has a market cap of $32.02 million, a price-to-earnings ratio of -0.19 and a beta of 0.70.

FibroGen (NASDAQ:FGEN – Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.09. The firm had revenue of $50.64 million for the quarter, compared to analyst estimates of $33.00 million. During the same period last year, the firm earned ($0.65) EPS. As a group, research analysts predict that FibroGen will post -0.91 EPS for the current year.

Institutional Trading of FibroGen

A number of large investors have recently bought and sold shares of the business. Acadian Asset Management LLC raised its holdings in shares of FibroGen by 34.4% in the second quarter. Acadian Asset Management LLC now owns 3,364,719 shares of the biopharmaceutical company’s stock valued at $2,997,000 after buying an additional 860,854 shares during the last quarter. AQR Capital Management LLC increased its position in FibroGen by 139.6% in the 2nd quarter. AQR Capital Management LLC now owns 1,320,866 shares of the biopharmaceutical company’s stock valued at $1,179,000 after acquiring an additional 769,586 shares during the period. Assenagon Asset Management S.A. purchased a new stake in FibroGen during the 3rd quarter valued at approximately $307,000. XTX Topco Ltd acquired a new stake in FibroGen during the 2nd quarter worth approximately $424,000. Finally, Cubist Systematic Strategies LLC grew its stake in shares of FibroGen by 3,906.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock valued at $256,000 after purchasing an additional 280,161 shares during the last quarter. Institutional investors and hedge funds own 72.71% of the company’s stock.

About FibroGen

(Get Free Report)

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.

Further Reading